BioCentury
ARTICLE | Company News

Abzena, Trieza deal

January 6, 2017 8:36 PM UTC

Abzena granted Trieza exclusive, worldwide rights to an undisclosed antibody sequence for use in combination with Trieza's viral vector technology to develop cancer treatments. The sequence was created using Abzena’s Composite Human Antibody technology. Abzena is eligible for up to $35 million in development and commercial milestones under the deal, plus royalties on products containing the sequence. ...

BCIQ Company Profiles

Abzena Ltd.